Start Date
October 1, 2023
Primary Completion Date
April 1, 2028
Study Completion Date
June 1, 2028
Pembrolizumab
Pembrolizumab intravenous (IV) infusion
Acasunlimab
Acasunlimab IV infusion
Cliniques Universitaires Saint-Luc, Brussels
UZ Leuven, Leuven
Universitair Ziekenhuis Ghent, Ghent
Aalborg University Hospital, Aalborg
Clínica Universidad de Navarra, Madrid
Hospital Universitario Ramón y Cajal, Madrid
Hospital Universitario 12 de Octubre, Madrid
Clínica Universidad de Navarra, Pamplona
Orlando Health Cancer Institute, Orlando
Rudgers Cancer Institute of New Jersey, New Brunswick
Grand Hospital de Charleroi, Charleroi
Rigshospitalet, Copenhagen
Odense Universitetshospital, Odense
AOU Policlinico Sant'Orsola Malpighi IRCCS, Bologna
IRCCS Istituto Europeo di Oncologia IEO, Milan
Fondazione G. Pascale, Napoli
IRCCS Policlinico Universitario Agostino Gemelli, Roma
Ospedale Mauriziano Umberto I, Torino
Keimyung University Dongsan Medical Center, Daegu
National Cancer Center Korea, Goyang-si
Pusan National University, Pusan
Seoul National University Bundang Hospital, Seongnam
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
"Severance Hospital, Yonsei University Health System, Division of Infectious Diseases"
Hospital Universitari Vall d'Hebron, Barcelona
ICO Girona, Girona
Hospital Universitario Fundacion Jiménez Díaz, Madrid
Lead Sponsor
Collaborators (1)
BioNTech SE
INDUSTRY
Genmab
INDUSTRY